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Abstract: Omega-3 polyunsaturated fatty acids (ω-3 PUFAs) are dietary factors involved in 
the prevention of cardiovascular, inflammatory, and neoplastic diseases. A multidisciplinary 
approach – based on recent findings in nutritional science, lipid biochemistry, biotechnology, 
and biology of inflammation and cancer – has been recently employed to develop ω-3 PUFA-
containing nanoformulations with an aim to protect these fatty acids from degradation, increase 
their bioavailability and delivery to target tissues, and, thus, enhance their bioactivity. In some 
cases, these nanoformulations were designed to administer ω-3 PUFAs in combination with 
other nutraceuticals or conventional/innovative drugs. The aim of this strategy was to increase 
the activities of the compounds contained in the nanoformulation and to reduce the adverse 
effects often induced by drugs. We herein analyze the results of papers evaluating the potential 
use of ω-3 PUFA-containing nanomaterials in fighting cardiovascular diseases and cancer. 
Future directions in this field of research are also provided.
Keywords: innovative biotechnologies, cardiovascular diseases, nanoparticles, ω-3 PUFAs, 
cancer
Introduction
There is a large body of evidence supporting a beneficial role of omega-3 polyunsaturated 
fatty acids (ω-3 PUFAs) against several pathologies, including cardiovascular diseases 
(CVDs) and cancer.1–3 The results have been obtained by using either the essential fatty 
acid α-linolenic acid (ALA, 18:3 ω-3), mostly found in vegetables and nuts or, and 
particularly, its metabolic products, the long-chain (LC)-ω-3 eicosapentaenoic acid 
(EPA, 20:5 ω-3) and docosahexaenoic acid (DHA, 22:6 ω-3). However, in mammal 
cells these two highly bioactive compounds are produced endogenously from ALA at 
very low levels; therefore, it is necessary to increase their main dietary sources (fish and 
seafood) to reach sufficient amounts in tissues. However, this requires a frequent intake 
of fish and seafood that appears unsustainable, particularly in the future.4 Moreover, 
wild fish is often contaminated with heavy metals or pesticides,5 whereas farmed fish 
contains much lower levels of LC-ω-3 PUFAs and high levels of antibiotics.6 In order 
to overcome these problems, alternative LC-ω-3 PUFA sources are now being explored, 
such as microalgae grown in controlled environments,7 or genetically modified plants 
and marine protists.8–11 An alternative approach may be the new nanotechnology-based 
strategies that are being developed to effectively deliver purified ω-3 PUFAs to the 
target tissues. These strategies are aimed to overcome the scarce solubility of these 
fatty acids, protect them from degradation, make them specifically active to target the 
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site of injury, and/or distribute them in strict combination 
with other bioactive compounds/drugs. The ultimate goal is 
to enhance their bioavailability, thus reducing the level of 
intake of these fatty acids or of other co-transported drugs.12–14 
For the first time, we have comprehensively and critically 
analyzed in the present review all the reports concerning 
the nanotechnological ω-3 PUFA-containing formulations 
hitherto developed, limiting our investigation to the in vitro 
and in vivo preclinical studies concerning the use of these 
nanoformulations in cellular and animal models of CVDs 
and cancers.
Literature search
A systematic literature search of the PubMed database was 
conducted from July 2017 to July 2018 to identify published 
peer-reviewed original articles regarding in vitro studies, 
in vivo animal studies, and human studies on the delivery 
of ω-3 PUFAs, alone, or in combination with other bioac-
tive compounds, through nanoformulations. The key words 
used for the search of titles and abstracts were: “omega-3” 
or “n-3 PUFA” or “docosahexaenoic acid” or “eicosapen-
taenoic acid” or “α-linolenic acid” or “fish oil;” and “animal 
studies,” or “in vitro studies,” or “in vivo studies” or “human 
studies;” and “nanoparticles” or “nanoformulations” and 
“encapsulation” and “delivery” and “nanomedicine” and 
“cancer” or “tumor” and “cardiovascular diseases” or “heart” 
and “inflammation.” We identified full-text articles written 
in English. The papers were chosen without restriction of 
time. We analyzed only the studies evaluating the biological 
effects of ω-3 PUFA nanoformulations and, in particular, in 
the cardiovascular and cancer conditions.
ω-3 PUFA-containing 
nanoformulations for the 
prevention of CVD and therapy
The prevention of CVDs is considered the main setting for 
ω-3 PUFA clinical application, and the major processes 
involved in the pathogenesis of most CVDs, including 
inflammation, oxidative stress, and abnormal cell 
proliferation,15,16 also represent the main targets of these fatty 
acids. However, the research investigating potential innova-
tive nanomedicine strategies in CVDs is still very scarce, 
and currently restricted only to occlusive vasculopathies and 
atherosclerosis17,18 (Table 1; Figure 1). In the first report on 
this topic, Deshpande et al17 investigated nanotechnology-
based approaches to deliver ω-3 PUFAs in combination 
with other nutraceuticals/drugs to vascular walls in order to 
prevent occlusive vasculopathies following vascular injuries. T
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The study was based on the recent observations demonstrating 
that ω-3 PUFAs and some of their bioactive metabolic deriva-
tives (ie, the specialized proresolving mediators, including 
resolvins, protectins, and maresins) are crucial endogenous 
signals to maintain vascular homeostasis, either by exerting 
anti-inflammatory properties,19 or by modulating the resolving 
phase of vascular injury and accelerating repair.20
In particular, ω-3 PUFAs and their derivatives have been 
considered potential anti-restenosis agents, and Deshpande 
et al17 included an ALA-rich oil (flaxseed oil) in an oil-in-
water nanoemulsion system they engineered for 17β-estradiol 
(17-βE) and C6-ceramide (CER) (Table 1; Figure 1). This 
combination appeared remarkably encouraging, since ALA 
has been largely reported to improve CV health, and both 
17-βE and CER were previously demonstrated to be cardio-
protective and vasoactive.21,22 However, it has been reported 
that their effect in vivo may be markedly reduced by a scarce 
release due to their high hydrophobicity and capability to bind 
with circulating proteins.23,24 In addition to the observation 
that the two cell systems related to restenosis (human aortic 
endothelial cells [ECs] and vascular smooth muscle cells 
[VSMCs]) showed a high in vitro uptake of 17-βE and CER, 
the most remarkable finding was a greater biological activity 
of the nanoemulsion compared to each single component 
administered alone (ie, increased or decreased platelet-derived 
growth factor-induced proliferation in EC and VSMC, respec-
tively).17 The authors explained the results on the basis of the 
more efficient delivery of 17-βE and CER to vascular cells 
when they were encapsulated in ALA-based nanodroplets. 
For the muscular cells, they associated the findings with the 
increased inhibitory effect exerted by encapsulated 17-βE on 
the p38 MAP-kinase activity, known to be involved in VSMC 
proliferation. In a more recent work by the group,18 the same 
flaxseed oil-based nanoemulsion encapsulating 17-βE was 
used with the clot-binding peptide cysteine–arginine–glu-
tamic acid–lysine–alanine, for its ability to selectively bind 
to the atherosclerotic plaque (Table 1; Figure 1). This strategy 
was aimed to specifically target atherosclerotic lesions and, 
thus, better counteract their development and progression. 
The nanoemulsion was administered either to EC cultured 
in vitro or, intravenously, to a mouse model of atheroscle-
rosis (apoE-/- mice fed a high-fat diet). The nanoemulsion 
components 17-βE and ALA were considered responsible for 
the increased production of nitric oxide by the EC cultured 
in vitro. They also minimally reduced the levels of plasma 
cholesterol and decreased the atherosclerotic plaque size, 
as well as the expression of atherosclerosis-related markers 
(intracellular adhesion molecule 1 (ICAM-1), vascular cell 
adhesion molecule 1 (VCAM-1), IL-6, tumor necrosis fac-
tor [TNF], etc.) within the aorta of the nanoemulsion-treated 
apoE-/- mice. The apoE-/- mice showed significantly 
increased levels of both triglycerides and cholesterol after 
a 10-week high-fat diet administration. Interestingly, the 
treatment with 17-βE and ALA containing nanoemulsion 
??????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????? ?????????????β???????????????????????????????????????????????????????????β????????????????????????????????????????????????????????????????
Figure 1 Potential use of ALA-containing nanoemulsions against the development of restenosis and atheroma. 
Note: The biological activity of nanoemulsions were evaluated in vitro or in vivo.
Abbreviations: ALA, α-linolenic acid; 17-βe, 17β-estradiol; CeR, C6-ceramide; CReKA, cysteine–arginine–glutamic acid–lysine–alanine.
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was able to slightly decrease, yet significantly, the level of 
plasma cholesterol which, conversely, remained unchanged 
when 17-βE was administered alone as a solution. The 
authors suggested that the marginal change in cholesterol 
induced by 17-βE and ALA nanoemulsion could partially 
contribute to the protective anti-atherosclerotic effects of the 
nanoparticles. However, they were induced to hypothesize 
that it was not responsible for the lesion-size reduction trig-
gered by these 17-βE/ALA nanoformulations, since previous 
observations in the same mouse model of atherosclerosis 
had shown that the levels of circulating cholesterol were not 
related to the size and area of the atherosclerotic lesion.25 
Probably, the endothelial modifications induced by the 
nanoemulsion could be responsible for the size reductions 
of the atherosclerotic lesions.
It is worth pointing out that a recent meta-analysis did 
not detect any result of increased dietary intake of ALA in 
the blood concentrations of the same inflammation markers 
(soluble ICAM and VCAM, IL-6, and TNF).26 This suggests 
that a more efficient delivery of ALA – such as the one 
demonstrated in the apoE-/- mouse model – could allow 
this fatty acid to reach vascular walls at adequate amounts to 
induce CV health effects, particularly if the delivery occurs 
in combination with other cardioprotective compounds 
(such as 17-βE).
ω-3 PUFA-containing 
nanoformulations for cancer 
prevention and therapy
Developed ω-3 PUFA-containing 
nanoformulations for liver cancer 
prevention and therapy
Most of the studies on new nanotechnology-based strategies 
for a more efficient delivery of ω-3 PUFAs to cancer cells 
in vitro and in vivo have been conducted on liver cells. A rel-
evant approach was used by the Corbin group.12,27–29 They 
created low-density lipoprotein (LDL)-based nanoparticles 
with DHA as bioactive cargo (Table 2; Figure 2A), and tested 
them on a normal mouse liver cell line, as well as on mice,12,28 
rats,29 or human liver cancer cell lines.27 Interestingly, this 
DHA nanoformulation was successfully employed by the 
same group of authors also for the delivery of DHA to the 
brain.30 In this case, they used the systemic administration 
of DHA-LDL nanoparticles combined with pulsed focused 
ultrasound exposures. In the LDL nanoparticles, DHA was 
placed inside the hydrophobic core, where its stability and 
biological activity can be preserved. The strategy of using 
LDLs as ω-3 PUFA transporters to liver cells has several 
advantages, since LDLs have a great capacity of carrying 
active substances, and they are naturally present in circu-
lation, so that they are not recognized and internalized by 
mononuclear circulating phagocytes.31 Moreover, LDLs carry 
and supply cells with lipids also in physiological conditions 
via LDL receptor-mediated endocytosis and seem particu-
larly suitable to deliver bioactive lipid factors to cancer cells, 
which show higher avidity for lipids than normal cells, due to 
their sustained membrane turnover.32–34 Indeed, one particu-
larly interesting feature of these engineered nanoparticles was 
their ability to be selectively cytotoxic to hepatocarcinoma 
cells, over the nonmalignant counterparts.12,28 This specific-
ity for cancer cells is highly advantageous for antineoplas-
tic agents, and, presumably, it was related to the fact that 
high concentrations of the cell growth inhibitor DHA were 
achieved only inside the cancer cells. Particularly, the selec-
tive growth-inhibitory effect of the LDL-DHA nanoparticles 
in liver cancer cells was explained on the basis of the specific 
and powerful anti-inflammatory and pro-resolving properties 
of the ω-3 PUFAs and their bioactive derivatives. Moreover, 
it was also related to increased levels of reactive oxygen spe-
cies (ROS) and iron found in cancer cells, as well as to the 
reported reduced glutathione (GSH) cellular depletion.35,36 
This pro-oxidative condition of cancer cells may easily induce 
peroxidation of a highly unsaturated compound, such as 
DHA.37 In turn, the peroxidation of intracellular membranes 
is triggered, and that may lead to lysosomal, mitochondrial, 
and nuclear disruption, and, lastly, cell death.28 Of great 
significance, a single intra-arterial injection of LDL-DHA 
in rats bearing transplanted orthotopic hepatocarcinoma 
markedly reduced tumor growth by altering redox balance 
and inducing tumor cell death.29 The most recent application 
of LDL-DHA particles by these authors convinced them to 
formulate the stimulating hypothesis that DHA enclosed in 
these particles could induce a recently described regulated 
type of necrotic cell death called ferroptosis in liver cancer 
cells.27 This non-apoptotic iron-dependent form of cell death38 
is characterized by the simultaneous intracellular occurrence 
of increased lipid peroxidation, high levels of intracellular 
ROS originating from iron metabolism, and glutathione 
depletion. Moreover, it is critically and negatively regulated 
by the lipid antioxidant enzyme glutathione peroxidase-4 
(GPX-4).27 In line with this, LDL-DHA also substantially 
reduced the expression and activity of GPX-4 in liver cancer 
cells, along with causing all the pro-oxidative changes typi-
cal of ferroptosis.27 Since it is usually reported that DHA – 
given as a free fatty acid – mainly causes apoptotic death 
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in cancer cells,39 the finding that LDL-DHA, on the other 
hand, triggers ferroptosis would imply that, depending on 
the delivery system used, ω-3 PUFAs may induce different 
death pathway inside the cells (ie, apoptosis or ferroptosis). 
The authors associated this effect to the fact that – while free 
DHA enters the cells by diffusion or facilitated transport40 – 
LDL-DHA nanoparticles are endocytosed in large amounts. 
This different entrance pathway into the cells could enable 
DHA to easily reach more internal subcellular structures and, 
thus, exert considerable effects on them, thus contributing to 
the ferroptotic pathway of cytotoxicity.27
Another interesting approach for the nanodelivery 
of ω-3 PUFAs was recently used to deliver ALA to 
diethylnitrosamine-induced hepatocarcinomas in mice.41 In 
this case, ALA was conjugated with 2,6-di-isopropylphenol, 
an anesthetic agent being structurally similar to vitamin E. 
The chemical structure of this conjugate was reported in 
Khan et al.42 This compound, conjugated with DHA, was 
previously shown to possess antioxidant properties and the 
ability to induce apoptosis and decrease the metastatic poten-
tial of human cancer cells.43 For an efficient delivery, the 
2,6-di-isopropylphenol-linolenic acid conjugate was enclosed 
in nanoliposomes tagged with the tetrapeptide tuftsin (Thr-
Lys-Pro-Arg),44 a fraction of the immunoglobulin G molecule 
(Table 2; Figure 2A). The use of tuftsin-tagged liposomes was 
previously and successfully used to deliver antibiotics in the 
area of infections,45 due to the immunomodulatory properties 
of tuftsin.44 It is worth highlighting that tuftsin was also previ-
ously administered in combination with antineoplastic drugs 
and shown to enhance their antitumor activity.46,47 The treat-
ment with tuftsin-tagged liposomes containing the ω-3 PUFA 
conjugate41 increased the survival of the hepatocarcinoma-
bearing mice, and this effect was partly related to the mark-
edly reduced expression of COX-2 and Bcl-2, as well as the 
upregulation of Bax observed in hepatocellular carcinomas. In 
our opinion, the co-presence of tuftsin and ω-3 PUFAs inside 
the same nanoliposomes is significant, since ω-3 PUFAs also 
show both immunomodulatory and antineoplastic activities 
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???????????
?????????
????????? ???????
???????????
?????
?ε??
???????????????
?????????????????????????????????????????????
?????????????
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Figure 2 Omega-3 PUFA-containing nanomaterials developed and evaluated in vitro or/and in vivo for their potential use against liver (A), breast (B) and lung (C) cancer.
Abbreviations: DHA, docosahexaenoic acid; LDL, low-density lipoprotein; LNA, linolenic acid; PeG, polyethylene glycol; PL, phospholipids; PεCL, poly-ε-caprolactone; 
PUFA, polyunsaturated fatty acid; SLN, solid lipid nanoparticle.
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at the same time, and their possible applications in the field 
of cancer immunotherapy have been recently suggested.48,49 
Moreover, due to the safe and non-toxic nature of both ω-3 
PUFAs and tuftsin and their common immunomodulating 
properties, the application of this liposomal delivery could 
be potentially useful, not only for the treatment of hepatocar-
cinoma, but also for its prevention in populations at high risk 
(such as hepatitis C virus (HCV)-positive patients, alcohol-
ics, or patients with inborn errors of metabolism, including 
type I glycogenosis or type I tyrosinemia).
Developed ω-3 PUFA-containing 
nanoformulations for breast cancer 
prevention and therapy
Roy et al50 developed polymeric nanoparticles (150–200 nm) 
encapsulating DHA (Table 3; Figure 2B) with the aim of 
using them in breast cancer. The polymeric wall of the nano-
capsules (NCs) consisted of poly-ε-caprolactone, a polyester 
able to protect the small liquid droplets of DHA included 
in the internal part (core) from chemical and enzymatic 
degradation, protecting DHA against the adverse conditions 
present in the gastrointestinal tract. This nanoencapsulation 
approach was previously used for the delivery of different 
drugs achieving positive results, such as enhanced drug 
efficacy and decreased drug toxicity.51 Roy et al50 observed 
a clear cytotoxic effect (measured by the MTT assay) when 
they administered 50–100 µM DHA in the form of free fatty 
acid for 4 days to MDA-MB-231 cultured in vitro, whereas 
lower concentrations showed no effect. This finding was 
in line with the results of several papers52–56 analyzed by us 
in a recent review,57 showing that treatments of the triple-
negative MDA-MB-231 or MDA-MB-453 breast cancer 
cells with EPA or/and DHA in the 30–100 µM range for 
1–5 days were necessary to inhibit cell growth and pro-
liferation, and to enhance apoptosis or breast cancer cell 
sensitivity to docetaxel (DTX). Unexpectedly, however, 
Roy et al50 found that, when lower concentrations of DHA 
(1–10 µM) were enclosed in NCs, they induced the prolif-
eration of MDA-MB-231 cancer cells. On the other hand, 
higher concentrations (30–50 µM) of encapsulated DHA 
reduced breast cancer cell proliferation, similarly to what 
was obtained with free DHA. The simultaneous presence 
of vitamin E inside the NCs eliminated the growth inhibit-
ing effect of DHA. Moreover, encapsulated DHA became 
more toxic than free DHA if H
2
O
2
 was added inside the 
NCs. Based on these results, the authors hypothesized that 
DHA should be oxidized and, thus, release secondary toxic 
products of lipid peroxidation which may be responsible for T
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its antiproliferative effects. However, the authors suggested 
that H
2
O
2
 could have also acted by disrupting the nanoparticle 
wall, releasing DHA outside the nanoparticles and, there-
fore, increasing its biological activity. Otherwise, due to its 
hydrophobic nature, this fatty acid tends to remain bound to 
the oily core of these nanoparticles and lose its bioactivity. 
Overall, however, the delivery of DHA to scarcely differ-
entiated breast cancer cells through this kind of polymeric 
nanoparticles does not appear promising for breast cancer 
therapy, as the antineoplastic activity of this fatty acid appears 
to decrease when it is encapsulated at high concentrations. 
Moreover, when it is encapsulated at lower concentrations, 
it seems to even promote breast cancer cell growth.50
On the other hand, Alaarg et al58 enclosed DHA 
into liposomes by using 1,2-dipalmitoyl-sn-glycero-
3-phosphocholine, cholesterol, and distearoyl phospha-
tidylethanolamine (PE); and polyethylene glycol (PEG) 
and these liposomes were used for the delivery of DHA to 
murine breast cancer cells in vitro (Table 3; Figure 2B). 
PEGylated liposomes were chosen for their acknowledged 
ability to stay in the circulation for a longer period (about 
1 day half-life) compared to non-PEGylated particles that are 
cleared from the circulation in #1 hour.59 This implies that 
a bioactive compound (in this case, DHA) enclosed in these 
nanoparticles can have more chances to be taken up by cells 
and tissues. DHA-loaded liposomes were able to inhibit the 
proliferation of murine 4T1 breast cancer cells, and other 
kinds of epithelial cells. However, it is worth underlining 
that, in this study, the effects induced by the DHA-loaded 
liposomes were compared only to those induced by the 
unloaded liposomes. For a clearer understanding, however, 
it would have been essential also to evaluate the effects of 
DHA administered in its free fatty acid form.
Skibinski et al60 evaluated the improvement in the 
bioactivity of DHA included in a different kind of lipo-
somes administered to MCF-7 and MDA-MB-231 breast 
cancer cells in vitro. Their DHA-loaded liposomes con-
tained 1,2-dihexadecyl-sn-glycero-3-phosphocholine 
and 1,2-diphytanyl-sn-glycero-3-phosphoethanolamine 
(Table 3; Figure 2B), phytanyl lipids similar to those present 
in Archaea prokaryotes and known to be highly resistant 
to pH and temperature changes. The authors observed that 
DHA loaded into the liposomes reduced more the viability 
of breast cancer cells and induced apoptosis more efficiently 
in both the cell lines. Inside the liposomes, only DHA was 
responsible for these effects, since the empty phytanyl lipid 
liposome did not significantly alter cell viability and apop-
tosis. Moreover, the authors found that DHA enclosed in the 
liposomes could more effectively decrease the expression of 
the activated form of Akt (p-AkT). They hypothesized that 
this effect could explain the increased antineoplastic activity 
showed by DHA loaded in the liposomes. This hypothesis is 
particularly interesting, since p-Akt represents a biomarker 
associated with poor prognosis in breast cancer, and used to 
evaluate the activity of the tyrosine kinase receptor signal-
ing, often deregulated in breast cancer carcinogenesis.57,61
A possible future ω-3 PUFA-containing nano-based 
approach for breast cancer may be suggested on the basis 
of the above analyzed remarkable results, obtained by both 
Alaarg et al58 and Skibinski et al60 with DHA-loaded nanoli-
posomes. Since ω-3 PUFAs are known to potentially act as 
an adjuvant therapy to strengthen the activity of conventional 
chemotherapeutics or targeted drugs in the therapy of breast 
cancer,57,62 it would be remarkable to develop nanoliposomal 
structures that are able to deliver simultaneously both ω-3 
PUFAs and drugs with previously acknowledged activity 
in breast cancer. This liposomal combined approach could 
also be experimented in the clinical setting, since some 
liposomes are known to be safe and have already been clini-
cally approved. Moreover, liposomes are able to encapsulate 
both hydrophobic and hydrophilic compounds and show a 
high capacity, making them particularly suitable to transport 
combinations of antineoplastic agents with different activities 
(conventional, targeted, or immunoactive agents),63 including 
also safe nutritional factors with multiple anticancer func-
tions, such as ω-3 PUFAs.
Developed ω-3 PUFA-containing 
nanoformulations for lung cancer 
prevention and therapy
To date, only two studies64,65 have evaluated the anticancer 
properties of ω-3 PUFA-containing nanoformulations on 
lung cancer cells (Table 4; Figure 2C), and their main 
aim was to improve the delivery and antitumor efficacy 
of doxorubicin (DOX) and DTX, two chemotherapeutic 
agents widely used in the therapy of solid tumors. A variety 
of nanotechnological approaches have been investigated 
so far to improve the limited uptake and distribution of 
DOX in solid tumors.66,67 Indeed, DOX is a weakly basic 
compound that becomes protonated when exposed to the 
slightly acidic pH of the microenvironment surrounding 
cancer cells, making its cellular uptake difficult.66 Liposomes, 
solid lipid nanoparticles (SLNs), and polymeric micelles are 
among the different types of DOX nanocarriers designed to 
overcome this problem. A PEGylated liposomal formulation 
containing DOX (Doxil) has also been approved for the 
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treatment of some cancers (ovarian cancer, AIDS-related 
Kaposi sarcoma, and multiple myeloma).68 Mussi et al64 
designed DOX-loaded SLN for lung cancer, where the oily 
phase included DHA and surfactants, such as Compritol, 
Tween 80, and triethanolamine (Table 4; Figure 2C). The 
SLN formulation allows a site-specific release of DOX in 
a slightly acidic environment, such as tumor tissues.66,69 
Moreover, the SLN solid matrix allows a more controlled 
release, and the lipophilicity of these nanoparticles improves 
the interaction with the cellular membranes. Furthermore, 
the SLNs obtained by encapsulating 0.4% DHA (w/v) were 
of smaller size (94±1 nm), which is advantageous, being 
the nanoparticles in the range of 100–200 nm taken up 
and retained at a higher concentration inside cancer cells 
compared to particles with a higher size.70–72 The simulta-
neous encapsulation of DOX with a lipophilic anion, such 
as DHA in the SLN, was aimed to overcome the low level 
of incorporation in lipidic nanostructures that DOX usually 
exhibits, due to its cationic amphiphilic nature. Moreover, 
the SLN exhibited negative charges due to the presence of 
DHA, and, inside the SLN, DOX formed an ion-pairing with 
DHA that could explain the high DOX encapsulation effi-
ciency (almost 100%), as well as the enhanced cytotoxicity 
shown by the DHA-DOX-loaded SLN against A549 lung 
adenocarcinoma cells, as compared to free DOX and DHA 
administered in combination.
The second study was performed by Zu et al,65 who 
evaluated the anticancer activity of ω-3 PUFA-containing 
polymeric nanoparticles on lung cancer cells. The nanopar-
ticle surface contained DHA covalently bound to BSA, 
a natural biodegradable polymer often used to prepare 
polymeric nanoformulations73 (Table 4; Figure 2C). Also 
in this case, the size of the newly developed nanoparticle 
(141.7±7.9 nm) was within the range of sizes allowing a 
more efficient uptake by cancer cells.70–72 The DHA-BSA 
nanoparticles were designed to enclose DTX, an approved 
semisynthetic antineoplastic drug belonging to the taxane 
family and, at present, largely used for the treatment of a 
variety of solid cancers, including lung and breast cancer.74,75 
Its inclusion in the nanoparticle was aimed to overcome the 
scarce aqueous solubility of the drug. Numerous formula-
tions of taxanes have been developed over the last decades in 
order to increase the aqueous solubility of the hydrophobic 
taxanes, such as cyclodextrin, liposomes, and albumin-bound 
nanoparticles (Abraxane) formulation.73,76 In the nanofor-
mulation analyzed,65 the addition of DHA to the albumin 
on the surface of the DTX-BSA nanoparticle was aimed 
to specifically target cancer cells, since it was previously 
observed that DHA preferentially accumulates in tumor cells 
and is considered a target ligand for cancer cells.77–79 This 
tumor targeting ability of DHA has been typically associated 
with the increased fluidity shown by cancer cell membranes 
which contain high levels of this fatty acid.77–79 In turn, the 
enhanced fluidity was related to their higher content in 
phospholipids, and, particularly, in PE, which was found 
to have a specific affinity for DHA.77 Above all, targeting 
lung cancer cells with these nanoparticles seems mainly 
appropriate since PE has been found to be overexpressed 
not only in the cancer cells used in this study (murine Lewis 
Lung Carcinoma [LLC] cells)77 but also, more in general, in 
the human non-small-cell lung cancers.80 Furthermore, the 
addition of an antineoplastic natural agent, such as DHA, 
to polymeric DTX-BSA nanoparticle65 was also related to 
the results of several human studies demonstrating that the 
therapeutic efficacy of this taxane can be increased after its 
conjugation to DHA, which is also able to decrease the side 
effects usually induced by taxane therapy, and improve the 
taxane delivery to the tumor tissues.81–86 Only the choice of 
BSA to prepare these polymeric nanoformulations could 
be controversial, since BSA was reported to antagonize the 
effect of DHA.13 The new DTX-DHA-BSA nanoparticles 
were administered to lung cancer cells cultured in vitro and 
to mice injected with syngeneic LLC cells in the tibia of 
the right limb, which mimicked lung cancer metastasis in 
the bone.65 The finding demonstrated that the simultaneous 
presence of DHA in the nanoparticles enhanced the anti-
cancer activity of taxanes both in vitro and in vivo, and also 
increased the mean survival time of the mouse.
Developed ω-3 PUFA-containing 
nanoformulations for prostate cancer 
prevention and therapy
Similarly to the results of the work by Zu et al,65 where nano-
formulations containing DHA bound to a taxane were tested 
in lung cancer, two studies performed on prostate cancer 
used an oil-in-water nanoemulsion formulation,87,88 where 
the starting oil phase consisted of fish oil with a novel DHA-
taxoid conjugate (DHA-SBT-1214) (Table 4; Figure 3A). 
The oil phase was mixed with the water phase formed by 
egg phosphatidylcholine (Lipoid E80®), polysorbate 80 
(Tween80®), and 1,2-distearoyl-sn-glycero-3-phosphoeth-
anolamine-N-(amino[polyethylene glycol]-2000) (DSPE-
PEG2000). Both the empty nanoemulsion (not containing 
drugs) and the nanoemulsion containing DHA-SBT-1214 
showed spherical shape and a very similar particle size 
(225±7 and 228±7 nm, respectively). The surface charge of 
the oil droplets in the two formulations did not change even 
using the maximum encapsulation of DHA-SBT-1214 within 
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the oil droplets. The two studies are remarkable, since they 
benefit from a new-generation taxoid (SBT-1214), bound 
to DHA, and avoid the use of albumin, which can reduce 
the anticancer effect of DHA.13 In particular, the use of 
SBT-1214 was aimed to overcome the mechanism through 
which placlitaxel89 or DTX90 was observed to induce drug 
resistance in prostate cancer (by mechanisms related to the 
induced expression of either P-glycoprotein or transform-
ing growth factor-β superfamily components, respectively). 
On the other hand, the rationale of SBT-1214 binding to DHA 
was related to the above-mentioned ω-3 PUFA ability to exert 
cancer-specific toxicity, to the synergistic antineoplastic 
effects that these fatty acids exert when bound to anticancer 
drugs, and to their ability to protect non-transformed prostate 
cells from cytotoxicity and reduce the secondary systemic 
harmful effects of conventional anticancer drugs, including 
taxanes. Moreover, the use of the non-ionic emulsifying 
agent Tween 80 in the preparation of this nanoemulsion 
is relevant, as it allows to obtain optimal oil droplet size 
and charge by inhibiting aggregation through competitive 
absorption to interfaces. This surfactant was also used for the 
preparation of other nanoemulsions containing ω-3 PUFAs 
and herein analyzed.64,91,92 The newly designed nanoemul-
sion of DHA-SBT-1214 (NE-DHA-SBT-1214) was tested 
for its antineoplastic activity against human prostatic cancer 
PPT2 cells cultured in vitro, or transplanted subcutaneously 
in NOD/SCID mice.87,88 These prostate cancer cells have the 
features of stem-like cells and are considered a good model 
for testing new drugs for prostate cancer. This is a highly 
recurrent tumor, which has been related to the presence of 
high levels of cancer stem cells with the potential of self-
renewing the tumor.93–95 The NE-DHA-SBT-1214 exerted 
higher cytotoxicity toward the PPT2 cells cultured in vitro, 
compared with DHA-SBT-1214 in solution. In addition, 
intravenous administrations of this nanoemulsion carrier 
system containing DHA-SBT-1214 in fish oil droplets to 
the transplanted mice markedly suppressed prostate cancer 
cell growth in vivo compared to a placebo nanoemulsion 
formulation previously approved for the treatment of 
metastastic human breast cancer (Abraxane™, ie, paclitaxel 
??????????????????????????????????????????? α?????????????????????
???????? ????? ????????????????????????????????????????????????????
?????????????????????????????????????
? ?
???????????????????????????????????????????????? ??????????
??????????????????????????????????????
Figure 3 Omega-3 PUFA-containing nanomaterials developed and evaluated in vitro or/and in vivo for their potential use against prostate (A), melanoma (B), and colorectal 
cancer (C).
Abbreviations: PUFA, polyunsaturated fatty acid; DHA, docosahexaenoic acid; SLN, solid lipid nanoparticle; ALA, α-linolenic acid.
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albumin-bound particles). Moreover, the prostate cancer 
cells that still remained viable after the in vivo treatment 
with NE-DHA-SBT-1214 had reduced neoplastic potential, 
which was shown by their decreased ability to give rise to 
colonies and spheres when analyzed ex vivo for clonogenic 
and sphere-forming capacities. These results suggest that 
the use of NE-DHA-SBT-1214 for the treatment of prostate 
cancer could be a promising strategy.
Developed ω-3 PUFA-containing 
nanoformulations for melanoma and 
colorectal cancer (CRC) prevention and 
therapy
We have studied the antineoplastic potential of ω-3 PUFAs 
in CRC and melanoma for many years96–101 and investigated 
the possible mechanisms underlying the beneficial action 
of these fatty acids. We have recently developed new SLNs 
for the delivery of ω-3 PUFAs to C32 melanoma cells91 and 
HT-29 and HCT116 CRC cells,92 to reduce possible ω-3 
PUFA oxidative degradation of these compounds, and, thus, 
prolong their shelf-life, enhance their bioavailability, and 
improve their antineoplastic activity (Table 5; Figure 3B 
and C). In particular, the matrix of the SLN tested in mela-
noma cells contained ALA esterified to α-tocopherol and 
encapsulated ALA itself. ALA carried in these nanoformula-
tions was always more cytotoxic than ALA or α-tocopherol 
administered alone to melanoma cells.91 On the other hand, 
the lipid matrix of the SLN formulation tested in CRC cells 
contained stearic acid esterified to the natural dietary anti-
oxidant resveratrol (RV). Furthermore, these RV-based SLN 
(RV-SLN) carried either ALA or DHA inside.92 Compared 
with the other SLN tested on melanoma cells, the substitution 
of ALA in the matrix with stearic acid was aimed to further 
increase the hydrophobicity of the encapsulated ω-3 PUFAs, 
thus potentially improving the efficiency of their delivery. 
Even though stearic acid is a saturated fatty acid, it has been 
shown that it may lower serum LDL cholesterol levels,102 and 
also protect from the development of prostate cancer.103,104 
In particular, this protective action appears remarkable, 
since it has been recently hypothesized that the incidence 
of prostate cancer may be associated with a high intake of 
ω-3 PUFAs. Thus, the combination stearic acid/ω-3 PUFAs 
inside the SLN could neutralize possible prostate-specific 
adverse effects of these fatty acids.105 Moreover, the encap-
sulation of both ALA and DHA makes them more efficient 
in inhibiting CRC cell growth, by enhancing their inhibitory 
effect on cell proliferation rather than further increasing their 
already high ability to induce apoptosis.92 These increased T
ab
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antineoplastic effects were strictly related to the enhanced 
cellular incorporation observed when DHA and ALA were 
enclosed in the RV-SLN to CRC cells. It was remarkable 
to find that, only after the encapsulation, ALA induced an 
evident cellular increase in both EPA and DHA and that 
encapsulated DHA was more efficiently retroconverted to 
EPA. This implies that the encapsulation of either DHA or 
ALA into RV-based SLN could also markedly increase the 
CRC content of EPA, which, according to several recent 
reports, seems to protect against CRC risk better than all the 
other main ω-3 PUFAs.106–108 The more efficient conversion 
of SLN-encapsulated ALA is particularly interesting when 
considering that ALA is present at high levels in a variety 
of seeds and vegetables, and its increased intake could be 
achieved more easily and in a more sustainable way com-
pared to an increased consumption of EPA itself.
In conclusion, it is important to underline that the pos-
sibility to further enhance the protective activity of these 
dietary compounds against CRC is appealing, since the 
possible prevention and treatment of CRC with PUFA has 
involved many researchers in the past two decades.96,109–112 
In particular, possible successful future investigations in the 
field of CRC nanomedicine-based therapy could be related 
to the powerful modulator effect recently demonstrated for 
ω-3 PUFAs on the intestinal microbiota.107,113 Indeed, since 
the microbiome may deeply affect the individual response to 
cancer immunotherapy, it would be worth investigating the 
approach of combined nanodelivery of immunomodulating 
innovative drugs, already used for CRC114,115 with ω-3 PUFAs 
against CRC in vivo. Moreover, co-delivering powerful anti-
inflammatory agents, such as ω-3 PUFAs, and these drugs in 
nanoparticles could also have the potential to overcome the 
severe colon immune-related adverse inflammatory events 
induced by these innovative treatments in CRC patients.116
Mixed and contrasting outcomes 
of recent human studies and the 
well-known benefits of ω-3 PUFAs 
in CVD and cancer
We cannot avoid focusing hereinafter on the topic outlined 
by the following question: are the contrasting outcomes of 
recent large human trials weakening the accepted dogma of 
ω-3 PUFA healthy effects? In our opinion, this topic deserves 
particular attention, particularly by the researchers who 
have been studying for decades the beneficial effects of ω-3 
PUFAs in the prevention of CVD and cancer.1,39,57,62,96,98,117 
Even though this issue cannot be tackled exhaustively in just 
one paragraph, it is essential to outline some considerations.
As far as the ω-3 PUFA cardioprotective role is con-
cerned, the beneficial outcomes of early human studies 
(epidemiological studies, prospective cohort studies, and 
randomized controlled trials) appear in contrast with the 
mixed or less positive results of some recent prospective 
trials, and meta-analysis of clinical trials.117 Indeed, they 
provided scarce or no evidence that ω-3 PUFA may reduce 
CV events or mortality (for a review see Bowen et al118). 
It has been hypothesized117 that these discrepancies may be 
attributed to the difficulty of ω-3 PUFA to induce healthy 
effects in a completely changed scenario. In fact, in recent 
years, the enrolled patients have often been simultaneously 
subject to the administration of statins and/or other pharmaco-
logic agents widely used to prevent CVD. Moreover, higher 
levels of ω-3 PUFA containing foods have been generally 
added to the diet following the numerous recommendations 
formulated over the last two decades. The results of the 
recently published VITAL study119 also obtained mixed and 
less promising results. It had the novelty of being a large, 
5-year randomized, double-blind, placebo-controlled trial of 
a daily fish oil supplementation (1 g, Omacor® fish oil) for 
primary prevention in healthy subjects at baseline. On the 
contrary, the earlier trials mostly evaluated whether a supple-
mentation with fish oil or purified ω-3 PUFAs could prevent 
CV adverse events in patients with a history of CVD or at 
high risk for CVD. Interestingly, the primary outcomes of 
the VITAL study indicated only a small but non-significant 
decrease in the rate of a major adverse CV event (ie, myo-
cardial infarction [MI] or stroke) in the ω-3 PUFA group 
with respect to the placebo group. However, a secondary 
analysis in those patients that were specifically affected 
by stroke or MI revealed that the intervention was able to 
significantly reduce the risk of MI (by 28%) and the death 
rate of MI (by 50%). Interestingly, a much higher reduction 
in MI risk (by 77%) was observed in the African subpopula-
tion, thus enforcing the notion that the ω-3 PUFA beneficial 
effects may be modified depending on the individual genetic 
background.120 Remarkably, the need for angioplasty was also 
significantly reduced (by 22%) by the fish oil supplementa-
tion. The accuracy of this trial was also demonstrated by the 
evaluation of the basal plasma ω-3 index (EPA + DHA as 
a percentage of total fatty acids) of the subjects, which was 
evaluated also after 1-year treatment to show its increase 
(by about 50%). The outcomes of another recently pub-
lished randomized double-blind, placebo-controlled trial 
(REDUCE-IT) reported more positive results. However, it 
evaluated the effects of simultaneous treatment with a very 
high dose (4 g/day) of purified EPA and statin therapy for 
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almost 5 years in patients with CVD or at high risk for CVD 
and high fasting triglyceride levels.121 The study showed 
that the EPA treatment reduced the levels of serum triglyc-
erides, CV events, and CV death. In particular, the rates of 
emergency or urgent revascularizations or MI were reduced 
by the EPA supplementation, even though the high dose 
used slightly increased the rate of bleeding events (see next 
paragraph), as well as the onset of atrial arrhythmias. It can 
be underlined that many differences do exist between these 
two most recent and largest trials, which can however help 
us to better understand the actual potential of ω-3 PUFAs in 
preventing CVD. For instance, the use of fish oil at a quite 
low dose may lack in showing the induction of health CV 
effects. On the contrary, EPA administered alone at a very 
high dose, even though in the presence of a statin therapy, 
may elicit beneficial effects, increasing, however, also the 
risk of some detrimental properties. Overall, the debate on 
the ω-3 PUFA-induced CV benefits is ongoing, also con-
sidering the manifold data from in vitro studies and in vivo 
animal studies supporting a variety of different biological 
and molecular mechanisms whereby ω-3 PUFA may confer 
coronary protection and reduce the risk of CVD.122 There-
fore, further large interventional trials comparing different 
doses and types of fatty acid (EPA and DHA) are needed 
for a better knowledge of this topic. Moreover, it would be 
more advantageous that the subjects/patients would be strati-
fied according to the ω-3 index expressed as the content of 
EPA and DHA in red cell membranes, which is considered 
a more reliable and stable indicator of the real ω-3 PUFA 
intake than their plasma level.123,124 Moreover, it would be 
important to evaluate the ω-3 index several times along the 
long-term studies.
With regard to cancer, plenty of evidence obtained 
from in vitro and in vivo preclinical studies has clearly 
indicated the anticancer activity of omega-3 PUFA.120 On 
the contrary, as we have widely discussed in a recent critical 
review of the literature,120 the results of the human studies 
are more controversial. In particular, most of the recent 
results confirmed the beneficial effects of the preclinical 
studies. However, there are studies where no effect was 
observed, or the antineoplastic effects were confined only 
to specific subpopulations (obese subjects, with specific 
dietary habits or with a particular fatty acid pattern, or 
having a specific T-cell infiltration in the tumor microen-
vironment). Only a few reports found positive associations 
between the development/progression of cancer (mainly 
for prostate cancer), and the high level of ω-3 PUFA 
introduced with the diet, present in blood, or accumulated 
in tissues. In our opinion, to clarify the issue, it would be 
essential to know the actual levels of ω-3 PUFA intake 
and the efficiency of their incorporation in the tissues of 
each subject along the study period. To this end, we rec-
ommended repeated evaluations of biomarkers reflecting 
the intake of ω-3 PUFAs, and in particular, the ω-3 index 
expressed as the content of EPA and DHA in red cell 
membranes.120 Moreover, we suggested, whenever pos-
sible, not to overlook some characteristics of the subjects 
being studied, such as the race/genetic background, and 
the metabolic/nutritional status.
Interestingly, the outcomes of the more recent interven-
tional VITAL study119 indicated that the daily supplementa-
tion with 0.8 g/day ω-3 EPA + DHA was unable to lower the 
incidence of different kinds of invasive cancer of any type, 
as well as that of colorectal, breast, and prostate cancer, or 
the incidence of death from cancer. These findings were 
consistent with the results of two recent meta-analyses of 
ω-3 PUFA trials of CVD that had shown either no asso-
ciation between the supplementations with ω-3 PUFA and 
the risk of cancer in general125 or a slightly increased but 
not significant risk.126 Again, however, attention should 
be focused on the doses supplemented and the consequent 
ω-3 PUFA tissue enrichment, that is, in our experience, the 
most related parameter to the antineoplastic activity of these 
fatty acids.124 It is possible that the daily dose of about 1.0 g 
(generally recommended for the secondary prevention of 
CVD) may not be sufficient to induce any anticancer effect. 
In a recently published review,124 we critically analyzed the 
doses of ω-3 PUFA that had been able to induce anticancer 
effects both in the animal studies and in the few available 
interventional human studies. We found that supplementa-
tion to humans with safe doses of EPA + DHA of ~2.0 g/day 
produced a plasma and tissue enrichment in these fatty acids 
of about 2–5 folds, which was associated with significant 
anticancer effects.127–129 Higher doses were not able to fur-
ther increase the amount of EPA and DHA incorporated in 
tissues. In mice or rats the dietary doses of EPA + DHA that 
have clear antineoplastic effects were variable in relation to 
their body mass and surface. However, these doses always 
produced an increase of ~2–5 folds of these fatty acids in 
the plasma, as well as in the normal and neoplastic tissues. 
Altogether, these observations prompted us to suggest that 
a daily dose of about 2 g could be the most appropriate for 
future human studies evaluating the anticancer effects of 
ω-3 PUFAs.
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Possible adverse effects of ω-3 
PUFAs: are they real obstacles 
to their use?
Increased bleeding risk
It is not possible to completely overlook here the controver-
sies regarding the possible adverse effects of high doses of 
ω-3 PUFAs. In particular, high intakes of ω-3 PUFAs have 
been suggested to exert adverse effects on bleeding risk, 
since, in an earlier study, the diet with high levels of ω-3 
PUFAs of the Greenland Inuit population was associated 
with an increased bleeding time.130 The finding that these fatty 
acids were able to displace the ω-6 PUFA arachidonic acid 
from cell membranes and decrease its metabolic conversion 
to the powerful pro-thrombotic platelet-aggregating factor 
thromboxane A2, further substantiated this hypothesis.96 
Moreover, increased intakes of ω-3 PUFAs were also 
reported to be associated with reduced blood levels of 
several clotting factors such as factor V, prothrombin, and 
von Willebrand factor.131 However, a recent review of the 
literature132 examining this issue supported the safe con-
sumption of EPA and DHA even in highly vulnerable and 
sensitive populations, such as patients having gastrointestinal 
cancer or hospitalized in Intensive Care Units and consum-
ing fish oil–enriched medical nutrition. No increased risk 
of bleeding-related event was identified in the analyzed 
reports, even if the patients were simultaneously treated with 
platelet aggregation inhibitors. On the contrary, the results 
concurred to support the safety of either very high daily doses 
of EPA + DHA given for a short period (up to 10 g/day) or 
much lower doses consumed for 1 year. Results obtained 
more recently by the large VITAL study having a 5-year 
median follow-up confirmed these findings.119 In this study, 
healthy subjects supplemented with 1 g/day fish oil (provid-
ing 460 mg EPA + 380 mg DHA) did not show increased 
major bleeding episodes as compared to the subjects of the 
placebo group. The other recent large REDUCE-IT study121 
was performed on patients already receiving statin therapy 
and showing high levels of serum triglycerides, patients with 
a previously diagnosed CVD or at high risk of developing 
CVD. They were supplemented for almost 5 years with a 
high daily dose (4 g) of purified EPA. This study reported 
a modestly but significantly higher overall rate of adverse 
events, but not fatal bleeding events in the EPA group (2.7% 
vs 2.1% in the placebo group). However, it was observed that 
there were no significant differences between the placebo end 
EPA groups in severe bleeding events, such as hemorrhagic 
stroke, serious central nervous system bleeding and gastro-
intestinal bleeding. Moreover, CV patients are often subject 
to chronic antithrombotic therapies, and this factor was not 
considered in the study. In any case, the inclusion of ω-3 
PUFA in nanoformulation and the consequent increased 
efficiency of their delivery and absorbance at specific sites 
may prevent the induction of adverse bleeding effects at the 
circulatory level.
Immunosuppression
Concern has also been expressed/raised over the possibility 
that ω-3 PUFAs could have the potential to suppress any pos-
sible basal immunoreactivity against cancer, and decrease the 
impact of cancer immunotherapy.133 This alarming possibility 
is related to the widely acknowledged anti-inflammatory and 
immunosuppressive activities of ω-3 PUFAs, and it is clear 
that their inclusion in nanoformulations to increase their 
bioactivity could also intensify these effects. However, in 
the last decades, a great deal of information has been gath-
ered supporting the anti-cancer activities of ω-3 PUFAs, 
which oppose the preconceived alarm of a possible ω-3 
PUFA cancer-promoting activity.120 Moreover, it should be 
underlined that, whereas acute inflammation is a response 
to antagonize infections, repair, and resolve tissue damage, 
chronic inflammation has been involved in the promo-
tion of cancer, by inducing immunosuppression in tumor 
microenvironment.134,135 Per se, it is considered a hallmark of 
cancer. To this respect, ω-3 PUFAs reveal their multifaceted 
nature, on one hand, by inhibiting persistent inflammation, 
thus preventing the promotion of cancer, and by also exerting 
pro-inflammatory actions to inhibit the immunosuppression 
existing in the tumor environment.136 In fact, recent findings 
have shown that one of the mechanisms through which ω-3 
PUFAs may inhibit tumor development in vivo is the induc-
tion of a local antitumor immune response.137,138 In particular, 
Liang et al137 demonstrated a decreased expression of markers 
of tumor-associated macrophages in the tumor microenviron-
ment of immunocompetent mice bearing prostate cancer and 
fed a fish oil–enriched diet. They also observed a decreased 
expression of a chemokine (CCL-2) that specifically recruits 
monocytes and macrophages to inflammatory sites.137 It was 
also hypothesized that more than the dietary intake of ω-3 
PUFAs by themselves, an increased dietary ω-3 PUFA/ω-6 
PUFA ratio could maximally and beneficially influence 
the immune characteristics of the tumor microenvironment 
and reduce the risk of developing some forms of cancer.139 
This was demonstrated by Gevariya et al138 that used mice 
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transplanted with syngeneic prostate transgenic cell line and 
supplemented with a high ω-3 PUFA/ω-6 PUFA ratio diet 
(3.3). They found increased levels of cytokines associated 
with Th1 and Th2 immune response in the tumors growing 
in these mice compared to those of mice fed a diet with 
a much lower ω-3 PUFA/ω-6 PUFA ratio (0.002). These 
findings are in line with recent in vitro studies showing 
that ω-3 PUFAs are able to stimulate the innate and the 
adaptive immune response, both in the humoral and in the 
cellular branch.140–142
Finally, considering the immunosuppressive activity of 
ω-3 PUFAs, it could be argued that they may have the poten-
tial to inhibit the immune response to infections. Again, this 
detrimental effect could be augmented by their inclusion in 
nanoformulations aimed to increase their efficacy. On the 
contrary, however, according to recent relevant results com-
prehensively analyzed by Costantini et al,143 dietary ω-3 PUFA 
can positively modulate the immune response to microbe 
infections. In particular, evidence has been provided that the 
strict relationship between ω-3 PUFAs, gut microbiota, and 
immune system may influence the activity of the host immune 
cells.143 In particular, plenty of animal studies and some evi-
dence in humans have demonstrated that dietary supplementa-
tions with ω-3 PUFAs are able to normalize the gut microbial 
imbalance.143 This appears interesting, since the intestinal 
microbiota has been reported to exert a crucial role in the 
development of the systemic and gut immune response.144,145
Conclusion
To date, only a limited number of recent studies performed 
in vitro or in animals have directly investigated the 
biological effects of newly developed ω-3 PUFA-containing 
nanomaterials in CVDs and cancer. To date, none of these 
nanoformulations have been tested in the clinical setting. The 
studies have almost univocally demonstrated that a more effi-
cient delivery of ω-3 PUFAs through these newly developed 
nanosystems may markedly enhance the therapeutic poten-
tial of nutraceuticals and other co-delivered drugs toward 
inflammatory lesions and cancer. Different strategies have 
been used, and these fatty acids have generally been included 
in the newly developed systems because of their ability to 
induce healthy effects. However, in some cases, they were 
also used just as a component of the lipidic phase to obtain 
nanoparticles carrying different bioactive products. More-
over, their position in the external part of some nanoparticles 
was also thought to specifically target cancer cells, which are 
avid of lipids necessary for their high-level metabolism and 
high proliferative turnover rate. Thus, through this expedient, 
such ω-3 PUFA-coated nanoparticles could be preferentially 
taken up by cancer cells.
Notably, the inclusion of these fatty acids – showing 
both anti-inflammatory and anti-neoplastic activities – in 
nanoformulations could be significant in making them more 
bioavailable and to better deliver them to cancer tissues. 
Therefore, ω-3 PUFAs could better inhibit cancer cell 
growth, but simultaneously decrease the adverse inflam-
matory effects induced by the currently used conventional 
and innovative antineoplastic agents and, also, reduce the 
cachexia associated with the advanced cancer stages.
It is worth observing that ALA becomes more bioactive 
when enclosed in some of the nanoformulations analyzed in 
this review. This happened since ALA in this form was more 
efficiently delivered to the target cells and converted into 
its more bioactive products (EPA and DHA). This implies 
that these ALA-containing nanoformulations could allow to 
easily enrich our tissues with EPA and DHA, which, unlike 
ALA, largely found in vegetables and nuts, are mainly 
obtained from fish that indeed are not considered a sustain-
able food source for the entire world population.
Altogether, the reports analyzed univocally suggest that 
multiple potential advantages could be obtained with the 
administration of nanoformulations containing ω-3 PUFAs 
for the prevention and cure of both CVDs and cancer. In par-
ticular, the inclusion in nanoparticles has been often designed 
to offer protection to these quite unstable compounds from 
oxidative insults and to increase and enhance their delivery to 
the sites of the pathological lesions, resulting in an increased 
efficacy. Moreover, the safety of ω-3 PUFAs at the doses 
generally used in human studies,124 their inexpensiveness, 
and the results so far obtained made them optimal candidates 
to be enclosed in nanoparticles in combination with other 
pharmacological agents already used in the clinical setting. 
The potential of these therapeutic combinations is to deliver 
all the agents enclosed successfully, increase their activity, 
and make the therapy more effective.
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